4DMT Reports FDA Clearance Of IND Application For 4D-175 Genetic Medicine For Treatment Of Geographic Atrophy

Author: Benzinga Newsdesk | June 24, 2024 08:04am

• 4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH)
  
   
• Complement factor H (CFH) variants with reduced function are a well-validated genetic risk factor for geographic atrophy (GA), with approximately 75% of age-related macular degeneration (AMD) patients carrying a high-risk variant of CFH
• Over 150 patients have been treated with the R100 vector, including those with wet AMD and diabetic macular edema, further validating the modularity of our Therapeutic Vector Evolution platform
  • Enrollment for Phase 1 GAZE clinical trial is expected to begin in H2 2024

Posted In: FDMT